Who
Robert G. Shawah
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Acurx Pharmaceuticals; Director, Enveric Biosciences; Chief Accounting Officer, Dipexium Pharmaceuticals.
In numbers
- Trades disclosed
- 14
- Buys
- 1
- Sells
- 0
- Bought
- $6,000
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 18 Mar 2014
- Last trade
- 20 Apr 2026
- Last filed
- 22 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,900 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,900 at $0.00 | filing |
| 5 Feb 2025filed 6 Feb 2025 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,500 at $0.00 | filing |
| 23 Feb 2024filed 3 Apr 2024 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 13 Feb 2023filed 24 Feb 2023 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2021filed 6 Jul 2021 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 29 Jun 2021filed 6 Jul 2021 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 20 Aug 2018filed 22 Aug 2018 | ENVB Enveric Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 20 Aug 2018filed 22 Aug 2018 | ENVB Enveric Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 17 Jan 2017filed 20 Apr 2017 | Dipexium Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 19 Jan 2016filed 21 Jan 2016 | Dipexium Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $660K65,000 at $10.16 | filing |
| 5 Jan 2015filed 29 Jan 2015 | Dipexium Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $397K35,000 at $11.35 | filing |
| 18 Mar 2014filed 19 Mar 2014 | Dipexium Pharmaceuticals | SEC FORM 4 Bought | $6,000500 at $12.00 | filing |
| 18 Mar 2014filed 19 Mar 2014 | Dipexium Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —85,379 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.